RayKnowChina Research Map
Shortlist

Other diseases

IgG4-related disease

IgG4相关性疾病IgG4-RD

A group of immune-related diseases that can affect many organs, with inflamed tissue rich in IgG4-positive plasma cells that can lead to scarring and organ damage.

Definition adapted from MeSH (US National Library of Medicine)

Listed in China's first national rare-disease catalogue (2018, no. 56). National Health Commission 国卫医发〔2018〕10号

hospitals in mainland China
46

with a paper from 2016–2025 or a registered study

cities
24

where those hospitals are

open trials in China
19

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 23% of the world's English-language research papers on IgG4-related disease, 2021–2025 (13% in 2016–2020), and 55% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

46 hospitals in 24 cities

Order: papers led on IgG4-related disease, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 2 papers or 1 trial on IgG4-related disease, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing11
  2. Shanghai4
  3. Taiyuan3
  4. Changsha2
  5. Chengdu2
  6. Guangzhou2
  7. Hangzhou2
  8. Shenyang2
  9. Shenzhen2
  10. Wuhan2

Each opens IgG4-related disease in that city. 14 more cities are in the menu below.

  1. 47 papers led
  2. 12 papers led
    No open trial led
  3. 12 papers led
  4. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    11 papers led
  5. 11 papers led
    No open trial led
  6. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    6 papers led
    No open trial led
  7. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    5 papers led
  8. 5 papers led
    No open trial led
  9. 5 papers led
    No open trial led
  10. 4 papers led
    No open trial led
  11. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    4 papers led
    No open trial led
  12. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    4 papers led
    No open trial led
  13. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    4 papers led
    No open trial led
  14. 3 papers led
    No open trial led
  15. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    3 papers led
    No open trial led
  16. 3 papers led
    No open trial led
  17. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    3 papers led
    No open trial led
  18. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    3 papers led
    No open trial led
  19. 3 papers led
    No open trial led
  20. 2 papers led
    No open trial led
  21. 2 papers led
    No open trial led
  22. 2 papers led
    No open trial led
  23. First Affiliated Hospital of Dali University

    大理大学第一附属医院(云南省第四人民医院)Dali

    2 papers led
    No open trial led
  24. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    2 papers led
    No open trial led
  25. 2 papers led
    No open trial led
  26. 2 papers led
    No open trial led
  27. 2 papers led
    No open trial led
  28. 2 papers led
    No open trial led
  29. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    2 papers led
    No open trial led
  30. Shenzhen Baoan Shiyan People's Hospital

    深圳市宝安区石岩人民医院Shenzhen

    2 papers led
    No open trial led
  31. 2 papers led
    No open trial led
  32. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    2 papers led
    No open trial led
  33. 2 papers led
    No open trial led
  34. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    1 paper led
    No open trial led
  35. West China Hospital of Stomatology

    四川大学华西口腔医院Chengdu

    1 paper led
    No open trial led
  36. Xiangya Hospital

    中南大学湘雅医院Changsha

    1 paper led
    No open trial led
  37. Xijing Hospital

    空军军医大学西京医院Xi'an

    1 paper led
    No open trial led
  38. Beijing Anzhen Hospital

    首都医科大学附属北京安贞医院Beijing

    0 papers led
    No open trial led
  39. 0 papers led
  40. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    0 papers led
  41. 0 papers led
  42. 0 papers led
    No open trial led
  43. 0 papers led
    No open trial led
  44. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    0 papers led
  45. Shanxi Bethune Hospital

    山西白求恩医院Taiyuan

    0 papers led
    No open trial led
  46. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    0 papers led
    No open trial led

By university or health system 21

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    47 papers led
    1 hospital
  2. Peking University Health Science Center

    北京大学医学部Beijing

    22 papers led
    4 hospitals
  3. Capital Medical University

    首都医科大学Beijing

    18 papers led
    4 hospitals
  4. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    13 papers led
    1 hospital
  5. Sichuan University (West China)

    四川大学华西Chengdu

    12 papers led
    2 hospitals
  6. China Medical University (Shenyang)

    中国医科大学Shenyang

    9 papers led
    2 hospitals
  7. Jilin University

    吉林大学Changchun

    7 papers led
    3 hospitals
  8. Fudan University

    复旦大学Shanghai

    6 papers led
    3 hospitals
  9. Sun Yat-sen University

    中山大学Guangzhou

    6 papers led
    3 hospitals
  10. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    6 papers led
    3 hospitals
  11. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    5 papers led
    1 hospital
  12. Central South University (Xiangya)

    中南大学湘雅Changsha

    4 papers led
    3 hospitals
  13. Tianjin Medical University

    天津医科大学Tianjin

    4 papers led
    2 hospitals
  14. Nanjing Medical University

    南京医科大学Nanjing

    3 papers led
    4 hospitals
  15. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    3 papers led
    2 hospitals
  16. Anhui Medical University

    安徽医科大学Hefei

    2 papers led
    2 hospitals
  17. Chongqing Medical University

    重庆医科大学Chongqing

    2 papers led
    1 hospital
  18. Naval Medical University

    海军军医大学Shanghai

    2 papers led
    2 hospitals
  19. Qingdao University

    青岛大学Qingdao

    2 papers led
    1 hospital
  20. Wenzhou Medical University

    温州医科大学Wenzhou

    2 papers led
    2 hospitals
  21. Nanjing University

    南京大学Nanjing

    1 paper led
    1 hospital

19

open trials on IgG4-related disease in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 16 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07061938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Chengdu, Shanghai, Wuhan

  2. Recruiting
    A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978647

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  3. Recruiting
    A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
    Phase
    Phase 2/Phase 3
    Started
    2025-07
    Registry
    NCT07068165

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  4. Recruiting
    A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT07104058

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  5. Recruiting
    Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07148791

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  6. Recruiting
    The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06285279

    Age 18 years to 65 years (registered criteria)

    Led by Jinling HospitalNanjing

  7. Recruiting
    Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497361

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  8. Recruiting
    Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
    Phase
    Early phase 1
    Started
    2024-07
    Registry
    NCT06497387

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  9. Recruiting
    BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06794008

    Age 18 years to 65 years (registered criteria)

    Led by Peking University People's HospitalBeijing

  10. Recruiting
    Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05789030

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  11. Recruiting
    National Registry of IgG4-RD in China
    Phase
    Not given
    Started
    2016-12
    Registry
    NCT03023371

    Age not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  12. Recruiting
    A Prospective Cohort Study of IgG4RD in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT01670695

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  13. Not yet recruiting
    Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07222553

    Age 2 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Changsha

  14. Not yet recruiting
    A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07593911

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  15. Not yet recruiting
    Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
    Phase
    Phase 3
    Started
    2026-08
    Registry
    NCT07719543

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  16. Not yet recruiting
    Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
    Phase
    Early phase 1
    Started
    2026-10
    Registry
    NCT07806045

    Age 18 years to 80 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  17. Not yet recruiting
    Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07878585

    Age 45 years to 79 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  18. Not yet recruiting
    UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06978738

    Age 18 years to Not stated (registered criteria)

    Led by Changzhou No.2 People's HospitalChangzhou

  19. Not yet recruiting
    An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07298590

    Age 18 years to 70 years (registered criteria)

    Led by Changhai HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions